BeyondSpring logo
BeyondSpring
BYSI | NASDAQ
Chart Builder DCF Calculator
$0.58
-$0.02 (-3.53%)
At close: Nov 16, 2026, 4:00 PM ET
$0.58
$0.00 (-0.21%)
After-hours: Nov 16, 2026, 4:10 PM ET

BeyondSpring Company Profile

Company profile explained

Company Profile

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

Key Executives

Name Position
Min Qiu Chief Executive Officer
Li Na Chief Financial Officer
John Mao Senior Vice President of Development
Joy Jia Vice President of Finance
June Lu Chief Scientific Officer
Lan Huang Co-Founder & Chair of the Board
Stephen Kilmer Head of Investor Relations

Latest SEC Filings

Date Type Title
Oct 29, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 13, 2026 8-K Current Report
Oct 06, 2026 8-K Current Report
Oct 02, 2026 8-K Current Report
Sep 29, 2026 8-K Current Report
Sep 29, 2026 424B5 Filing
Sep 18, 2026 8-K Current Report
Sep 03, 2026 DEFA14A Filing
Sep 03, 2026 DEF 14A Filing
Sep 03, 2026 ARS Filing
View All SEC Filings ➞
BeyondSpring
BeyondSpring logo
Country United States
IPO Date Mar 9, 2017
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Qiu Min

Contact Details

100 Campus Drive Florham Park, New York 07932 United States

Stock Details

Ticker Symbol BYSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001677940
CUSIP Number G10830100
ISIN Number KYG108301006
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.